Corresponding Author: James A. de Lemos, MD, Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5909 Harry Hines Blvd, Dallas, TX 76390 (james.delemos@utsouthwestern.edu).
Accepted for Publication: February 1, 2021.
Author Contributions: Drs Joshi and de Lemos had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Both authors.
Drafting of the manuscript: Joshi.
Critical revision of the manuscript for important intellectual content: Both authors.
Administrative, technical, or material support: Joshi.
Supervision: de Lemos.
Conflict of Interest Disclosures: Dr Joshi reported receiving grant support from the American Heart Association, NASA, Novartis, Novo Nordisk, Sanofi, GlaxoSmithKline, AstraZeneca, and Pfizer; receiving personal fees from Bayer and Regeneron; and having an equity interest in G3 Therapeutics. Dr de Lemos reported receiving grant support from the National Institutes of Health, the American Heart Association, the National Space Biomedical Research Institute, Roche Diagnostics, and Abbott Diagnostics; receiving personal income from Novo Nordisk, Amgen, Regeneron, Eli Lilly, Abbott Diagnostics, Siemens Healthcare Diagnostics and Ortho Clinical Diagnostics for serving on data monitoring committees, steering committees, or end point committees; and receiving consulting income from Janssen and Quidel Inc.
1.Virani
SS , Alonso
A , Benjamin
EJ ,
et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
Circulation. 2020;141(9):e139-e596. doi:
10.1161/CIR.0000000000000757PubMedGoogle ScholarCrossref 3.Fihn
SD , Gardin
JM , Abrams
J ,
et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
Circulation. 2012;126(25):e354-e471.
PubMedGoogle Scholar 4.Fihn
SD , Blankenship
JC , Alexander
KP ,
et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
Circulation. 2014;130(19):1749-1767. doi:
10.1161/CIR.0000000000000095PubMedGoogle ScholarCrossref 12.O’Gara
PT , Kushner
FG , Ascheim
DD ,
et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2013;127(4):e362-e425. doi:
10.1161/CIR.0b013e3182742c84PubMedGoogle ScholarCrossref 13.Amsterdam
EA , Wenger
NK , Brindis
RG ,
et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Circulation. 2014;130(25):e344-e426. Published correction appears in
Circulation. 2014;130(25):e433-e434.
PubMedGoogle Scholar 14.Narula
J , Nakano
M , Virmani
R ,
et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques.
J Am Coll Cardiol. 2013;61(10):1041-1051. doi:
10.1016/j.jacc.2012.10.054PubMedGoogle ScholarCrossref 18.Eisen
A , Bhatt
DL , Steg
PG ,
et al; REACH Registry Investigators. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
J Am Heart Assoc. 2016;5(10):e004080. doi:
10.1161/JAHA.116.004080PubMedGoogle Scholar 20.Hemingway
H , Langenberg
C , Damant
J , Frost
C , Pyörälä
K , Barrett-Connor
E . Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries.
Circulation. 2008;117(12):1526-1536. doi:
10.1161/CIRCULATIONAHA.107.720953PubMedGoogle ScholarCrossref 21.Reynolds
HR , Shaw
LJ , Min
JK ,
et al; ISCHEMIA Research Group. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: secondary analysis of the ISCHEMIA randomized clinical trial.
JAMA Cardiol. 2020;5(7):773-786. doi:
10.1001/jamacardio.2020.0822PubMedGoogle ScholarCrossref 23.Walker
S , Asaria
M , Manca
A ,
et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER).
Eur Heart J Qual Care Clin Outcomes. 2016;2(2):125-140. doi:
10.1093/ehjqcco/qcw003PubMedGoogle ScholarCrossref 26.De Bruyne
B , Pijls
NH , Kalesan
B ,
et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
N Engl J Med. 2012;367(11):991-1001. Published correction appears in
N Engl J Med. 2012;367(18):1768. doi:
10.1056/NEJMoa1205361PubMedGoogle ScholarCrossref 28.Shaw
LJ , Berman
DS , Picard
MH ,
et al; National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored ISCHEMIA Trial Investigators. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging.
JACC Cardiovasc Imaging. 2014;7(6):593-604. doi:
10.1016/j.jcmg.2013.10.021PubMedGoogle ScholarCrossref 32.Shaw
LJ , Bairey Merz
CN , Pepine
CJ ,
et al; WISE Investigators. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.
J Am Coll Cardiol. 2006;47(3)(suppl):S4-S20. doi:
10.1016/j.jacc.2005.01.072PubMedGoogle ScholarCrossref 35.Beltrame
JF , Weekes
AJ , Morgan
C , Tavella
R , Spertus
JA . The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) study.
Arch Intern Med. 2009;169(16):1491-1499. doi:
10.1001/archinternmed.2009.295PubMedGoogle ScholarCrossref 36.Dagenais
GR , Armstrong
PW , Théroux
P , Naylor
CD ; CCS Ad Hoc Committee for Revising the CCS Grading of Stable Angina. Revisiting the Canadian Cardiovascular Society grading of stable angina pectoris after a quarter of a century of use.
Can J Cardiol. 2002;18(9):941-944.
PubMedGoogle Scholar 39.Omland
T , Sabatine
MS , Jablonski
KA ,
et al; PEACE Investigators. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial.
J Am Coll Cardiol. 2007;50(3):205-214. doi:
10.1016/j.jacc.2007.03.038PubMedGoogle ScholarCrossref 40.Omland
T , de Lemos
JA , Sabatine
MS ,
et al; Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease.
N Engl J Med. 2009;361(26):2538-2547. doi:
10.1056/NEJMoa0805299PubMedGoogle ScholarCrossref 43.Genders
TS , Steyerberg
EW , Hunink
MG ,
et al. Prediction model to estimate presence of coronary artery disease: retrospective pooled analysis of existing cohorts.
BMJ. 2012;344:e3485. doi:
10.1136/bmj.e3485PubMedGoogle Scholar 44.Bittencourt
MS , Hulten
E , Polonsky
TS ,
et al. European Society of Cardiology-recommended Coronary Artery Disease Consortium pretest probability scores more accurately predict obstructive coronary disease and cardiovascular events than the Diamond and Forrester Score: the Partners registry.
Circulation. 2016;134(3):201-211. doi:
10.1161/CIRCULATIONAHA.116.023396PubMedGoogle ScholarCrossref 46.Knuuti
J , Ballo
H , Juarez-Orozco
LE ,
et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability.
Eur Heart J. 2018;39(35):3322-3330. doi:
10.1093/eurheartj/ehy267PubMedGoogle ScholarCrossref 47.Yang
K , Yu
SQ , Lu
MJ , Zhao
SH . Comparison of diagnostic accuracy of stress myocardial perfusion imaging for detecting hemodynamically significant coronary artery disease between cardiac magnetic resonance and nuclear medical imaging: a meta-analysis.
Int J Cardiol. 2019;293:278-285. doi:
10.1016/j.ijcard.2019.06.054PubMedGoogle ScholarCrossref 48.Montalescot
G , Sechtem
U , Achenbach
S ,
et al; Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Eur Heart J. 2013;34(38):2949-3003. doi:
10.1093/eurheartj/eht296PubMedGoogle ScholarCrossref 52.Min
JK , Dunning
A , Lin
FY ,
et al; CONFIRM Investigators. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings: results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease.
J Am Coll Cardiol. 2011;58(8):849-860. doi:
10.1016/j.jacc.2011.02.074PubMedGoogle ScholarCrossref 53.Voros
S , Rinehart
S , Qian
Z ,
et al. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis.
JACC Cardiovasc Imaging. 2011;4(5):537-548. doi:
10.1016/j.jcmg.2011.03.006PubMedGoogle ScholarCrossref 54.Budoff
MJ , Dowe
D , Jollis
JG ,
et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial.
J Am Coll Cardiol. 2008;52(21):1724-1732. doi:
10.1016/j.jacc.2008.07.031PubMedGoogle ScholarCrossref 57.Arbab-Zadeh
A , Miller
JM , Rochitte
CE ,
et al. Diagnostic accuracy of computed tomography coronary angiography according to pre-test probability of coronary artery disease and severity of coronary arterial calcification: the CORE-64 (Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography) international multicenter study.
J Am Coll Cardiol. 2012;59(4):379-387. doi:
10.1016/j.jacc.2011.06.079PubMedGoogle ScholarCrossref 61.Bittencourt
MS , Hulten
EA , Murthy
VL ,
et al. Clinical outcomes after evaluation of stable chest pain by coronary computed tomographic angiography versus usual care: a meta-analysis.
Circ Cardiovasc Imaging. 2016;9(4):e004419. doi:
10.1161/CIRCIMAGING.115.004419PubMedGoogle Scholar 63.Hoffmann
U , Ferencik
M , Udelson
JE ,
et al; PROMISE Investigators. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).
Circulation. 2017;135(24):2320-2332. doi:
10.1161/CIRCULATIONAHA.116.024360PubMedGoogle ScholarCrossref 64.Lu
MT , Douglas
PS , Udelson
JE ,
et al. Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: a randomized comparison of test complications, incidental findings, and radiation dose.
J Cardiovasc Comput Tomogr. 2017;11(5):373-382. doi:
10.1016/j.jcct.2017.08.005PubMedGoogle ScholarCrossref 66.Celeng
C , Leiner
T , Maurovich-Horvat
P ,
et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis.
JACC Cardiovasc Imaging. 2019;12(7 pt 2):1316-1325. doi:
10.1016/j.jcmg.2018.07.022PubMedGoogle ScholarCrossref 69.Fairbairn
TA , Nieman
K , Akasaka
T ,
et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE registry.
Eur Heart J. 2018;39(41):3701-3711. doi:
10.1093/eurheartj/ehy530PubMedGoogle ScholarCrossref 70.Mahmoudi
M , Nicholas
Z , Nuttall
J ,
et al. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: rationale and design of the FORECAST trial.
Cardiovasc Revasc Med. 2020;21(7):890-896.
PubMedGoogle ScholarCrossref 72.Dinu
M , Pagliai
G , Casini
A , Sofi
F . Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials.
Eur J Clin Nutr. 2018;72(1):30-43. doi:
10.1038/ejcn.2017.58PubMedGoogle ScholarCrossref 74.Anderson
L , Thompson
DR , Oldridge
N ,
et al. Exercise-based cardiac rehabilitation for coronary heart disease.
Cochrane Database Syst Rev. 2016;(1):CD001800.
PubMedGoogle Scholar 75.Baigent
C , Blackwell
L , Emberson
J ,
et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010;376(9753):1670-1681. doi:
10.1016/S0140-6736(10)61350-5PubMedGoogle ScholarCrossref 77.AlTurki
A , Marafi
M , Dawas
A ,
et al. Meta-analysis of randomized controlled trials assessing the impact of proprotein convertase subtilisin/kexin type 9 antibodies on mortality and cardiovascular outcomes.
Am J Cardiol. 2019;124(12):1869-1875. doi:
10.1016/j.amjcard.2019.09.011PubMedGoogle ScholarCrossref 79.Baigent
C , Blackwell
L , Collins
R ,
et al; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Lancet. 2009;373(9678):1849-1860. doi:
10.1016/S0140-6736(09)60503-1PubMedGoogle ScholarCrossref 80.Connolly
SJ , Eikelboom
JW , Bosch
J ,
et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Lancet. 2018;391(10117):205-218. doi:
10.1016/S0140-6736(17)32458-3PubMedGoogle ScholarCrossref 81.Whelton
PK , Carey
RM , Aronow
WS ,
et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension. 2018;71(6):1269-1324. doi:
10.1161/HYP.0000000000000066PubMedGoogle ScholarCrossref 83.Zelniker
TA , Wiviott
SD , Raz
I ,
et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet. 2019;393(10166):31-39. doi:
10.1016/S0140-6736(18)32590-XPubMedGoogle ScholarCrossref 84.Kristensen
SL , Rørth
R , Jhund
PS ,
et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol. 2019;7(10):776-785. doi:
10.1016/S2213-8587(19)30249-9PubMedGoogle ScholarCrossref 91.Grundy
SM , Stone
NJ , Bailey
AL ,
et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019;139(25):e1082-e1143.
PubMedGoogle Scholar 92.Silverman
MG , Ference
BA , Im
K ,
et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.
JAMA. 2016;316(12):1289-1297. doi:
10.1001/jama.2016.13985PubMedGoogle ScholarCrossref 93.Cannon
CP , Blazing
MA , Braunwald
E . Ezetimibe plus a statin after acute coronary syndromes.
N Engl J Med. 2015;373(15):1476-1477.
PubMedGoogle Scholar 94.Sabatine
MS , Giugliano
RP , Keech
AC ,
et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.
N Engl J Med. 2017;376(18):1713-1722. doi:
10.1056/NEJMoa1615664PubMedGoogle ScholarCrossref 96.Nicholls
SJ , Lincoff
AM , Garcia
M ,
et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.
JAMA. 2020;324(22):2268-2280. doi:
10.1001/jama.2020.22258PubMedGoogle ScholarCrossref 100.Levine
GN , Bates
ER , Bittl
JA ,
et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.
Circulation. 2016;134(10):e123-e155.
PubMedGoogle ScholarCrossref 102.Das
SR , Everett
BM , Birtcher
KK ,
et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
J Am Coll Cardiol. 2018;72(24):3200-3223. doi:
10.1016/j.jacc.2018.09.020PubMedGoogle ScholarCrossref 103.Arnold
SV , Bhatt
DL , Barsness
GW ,
et al; American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association.
Circulation. 2020;141(19):e779-e806. doi:
10.1161/CIR.0000000000000766PubMedGoogle ScholarCrossref 104.Tsimikas
S , Karwatowska-Prokopczuk
E , Gouni-Berthold
I ,
et al; AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease.
N Engl J Med. 2020;382(3):244-255. doi:
10.1056/NEJMoa1905239PubMedGoogle ScholarCrossref 109.Belsey
J , Savelieva
I , Mugelli
A , Camm
AJ . Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis.
Eur J Prev Cardiol. 2015;22(7):837-848. doi:
10.1177/2047487314533217PubMedGoogle ScholarCrossref 111.Yusuf
S , Zucker
D , Peduzzi
P ,
et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.
Lancet. 1994;344(8922):563-570. doi:
10.1016/S0140-6736(94)91963-1PubMedGoogle ScholarCrossref 113.Shaw
LJ , Weintraub
WS , Maron
DJ ,
et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.
Am Heart J. 2012;164(2):243-250. doi:
10.1016/j.ahj.2012.05.018PubMedGoogle ScholarCrossref 115.Head
SJ , Milojevic
M , Daemen
J ,
et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
Lancet. 2018;391(10124):939-948. doi:
10.1016/S0140-6736(18)30423-9PubMedGoogle ScholarCrossref 116.Ahmad
Y , Howard
JP , Arnold
AD ,
et al. Mortality after drug-eluting stents vs coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.
Eur Heart J. 2020;41(34):3228-3235. doi:
10.1093/eurheartj/ehaa135PubMedGoogle ScholarCrossref 118.Al-Lamee
R , Howard
JP , Shun-Shin
MJ ,
et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease.
Circulation. 2018;138(17):1780-1792. doi:
10.1161/CIRCULATIONAHA.118.033801PubMedGoogle ScholarCrossref 119.Al-Lamee
RK , Shun-Shin
MJ , Howard
JP ,
et al. Dobutamine stress echocardiography ischemia as a predictor of the placebo-controlled efficacy of percutaneous coronary intervention in stable coronary artery disease: the stress echocardiography-stratified analysis of ORBITA.
Circulation. 2019;140(24):1971-1980. doi:
10.1161/CIRCULATIONAHA.119.042918PubMedGoogle ScholarCrossref